400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR2500099134
尚未开始
/
/
/
2025-03-19
/
/
Nil
Effect of an evidence-based assessment instrument to minimize the use of physical restraint in general adult ward settings in Hong Kong: A cluster randomized controlled trial
Effect of an evidence-based assessment instrument to minimize the use of physical restraint in general adult ward settings in Hong Kong: A cluster randomized controlled trial
The objectives of this research are to evaluate the effect of the evidence-based assessment instrument to minimize the use of PR in general adult ward settings, and the process evaluation and satisfaction of the evidence-based assessment instrument when applying in general adult ward settings in Hong Kong.
整群随机分组
其它
A single blinded cluster randomized controlled trial will be conducted in a total of eight wards within the department of Medicine & Geriatrics (M&G), the department of Orthopaedics & Traumatology (O&T), and the Department of Surgery (SUR) from 8th April to 9th June 2025 at UCH. Two wards from O&T and SUR, along with four wards from M&G, will be randomly assigned using simple random sampling.
A single blinded cluster randomized controlled trial will be conducted as the patient does not know which group they are allocated.
Nil
/
932
/
2025-03-25
2025-06-09
/
Participants aged 18 or above and admitted to the general adult ward settings at the research sites within the hospital are eligible to participate in the study. All nurses who provide direct patient care, will be included for the process evaluation and satisfaction review.;
请登录查看For the clinical study, there are no exclusion criteria, as all patients are under treatment and care during hospitalization. Participation in the evaluation is voluntary for healthcare providers who wish to give feedback and participate in the survey.;
请登录查看United Christian Hospital, Hong Kong Hospital Authority
/
求实药社2026-03-05
生物制品圈2026-03-05
医药观澜2026-03-05
医药观澜2026-03-05
河北省干细胞中心2026-03-05
生物制药小编2026-03-05
一度医药2026-03-05
炎明生物Pyrotech2026-03-05
药明康德2026-03-05
疑夕随笔2026-03-04